Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amicus Therapeutics
Amicus Therapeutics raises $60 million series D financing
October 13th, 2006
Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced the closing of a $60 million Series D financing, the company's largest to date, led by New Enterprise Associates (NEA). In August, due to market conditions, the company withdrew its S-1 registration statement with the Securities and Exchange Commission (SEC) relating to a proposed initial public offering. In this financing round, NEA was joined by current investors Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, Palo Alto Investors, Prospect...
Source: Medicine & Law Weekly (2006-10-13)
|
